HCV in children and pregnancy

Hepatitis C Virus (HCV) in Children and Pregnancy

Hepatitis C is a liver disease caused by the Hepatitis C Virus (HCV), which can result in both acute and chronic hepatitis infection. The transmission of HCV can occur through exposure to small quantities of blood, which can happen through various means such as intravenous drug use, improper sterilization of medical equipment, and transfusions of unscreened blood and blood products. In the context of children and pregnancy, the primary concern is the vertical transmission (mother-to-child transmission) of the virus.

Transmission

The risk of HCV transmission from an infected mother to her child occurs primarily at the time of birth. The rate of vertical transmission is approximately 5-6%, but this rate can increase in the presence of high maternal viral loads or co-infection with HIV. Unlike Hepatitis B, there is no available vaccine or proven effective prophylactic treatment to prevent the transmission of HCV from mother to child.

Diagnosis

In children, the diagnosis of HCV is complicated by the passive transfer of maternal antibodies, which can persist up to 18 months of age. Therefore, HCV RNA testing is recommended after 1 year of age to confirm the diagnosis in infants born to HCV-infected mothers. For pregnant women, screening for HCV is recommended as part of prenatal care, especially for those with known risk factors for HCV infection.

Management

Management of HCV in pregnancy aims to monitor the health of the mother and reduce the risk of vertical transmission. Antiviral therapy with direct-acting antivirals (DAAs) has revolutionized the treatment of HCV in adults; however, their use in pregnancy is not well established due to limited data on safety and efficacy. Therefore, treatment of HCV in pregnant women is usually deferred until after delivery.

For children with chronic HCV infection, treatment options have expanded with the approval of DAAs for pediatric use. The goal of treatment is to achieve a sustained virologic response (SVR), which is indicative of viral clearance. Early treatment is associated with better outcomes and reduced risk of long-term liver complications.

Prevention

Preventive measures for HCV in children and during pregnancy focus on reducing the risk of mother-to-child transmission. This includes screening and identifying HCV-infected pregnant women, avoiding invasive procedures during delivery that could increase the risk of blood exposure, and considering cesarean delivery in certain cases with high viral loads or HIV co-infection.

Conclusion

HCV in children and pregnancy presents unique challenges in terms of transmission, diagnosis, and management. With ongoing research and the potential for new treatments, there is hope for reducing the impact of HCV on mothers and their children. Early diagnosis and appropriate management are key to preventing long-term complications associated with HCV infection.

‎